Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
08:01am, Tuesday, 24'th Sep 2024
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a c
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
04:30pm, Monday, 16'th Sep 2024
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK , Sept.
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK , Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
07:51am, Tuesday, 03'rd Sep 2024
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Lucid
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Com
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
08:16am, Tuesday, 13'th Aug 2024
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK , Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnos
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
08:01am, Tuesday, 13'th Aug 2024
Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financi
Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript
01:32pm, Monday, 12'th Aug 2024
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Dr. Lishan Aklog - Chairman, Chief Executive Officer Dennis McGrath - Chief Finan
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
08:07am, Monday, 12'th Aug 2024
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume #CheckYourFoodT
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
08:31am, Thursday, 08'th Aug 2024
Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health NEW YORK , Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a comm
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
08:15am, Tuesday, 06'th Aug 2024
Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostic
Lucid Diagnostics to Participate in Upcoming Investor Conferences
08:15am, Monday, 05'th Aug 2024
NEW YORK , Aug. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVm
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
08:15am, Monday, 29'th Jul 2024
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention me
3 Hypergrowth Stocks That Speculators Should Keep Tabs On
06:00am, Monday, 29'th Jul 2024
Hypergrowth stocks isn't so much about returns as it is time. Don't get me wrong: when you think about the words “hyper” and “growth,” the price moving in the northward direction along the y-a
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
08:01am, Tuesday, 23'rd Jul 2024
Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, ca
